Zevra Therapeutics Inc (ZVRA)
8.92
+0.28
(+3.24%)
USD |
NASDAQ |
Nov 14, 12:40
Zevra Therapeutics Research and Development Expense (Quarterly): 10.52M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 10.52M |
| March 31, 2024 | 12.28M |
| December 31, 2023 | 11.23M |
| September 30, 2023 | 12.30M |
| June 30, 2023 | 7.433M |
| March 31, 2023 | 8.655M |
| December 31, 2022 | 6.541M |
| September 30, 2022 | 5.385M |
| June 30, 2022 | 22.46M |
| March 31, 2022 | 3.082M |
| December 31, 2021 | 2.809M |
| September 30, 2021 | 2.239M |
| June 30, 2021 | 2.848M |
| March 31, 2021 | 2.265M |
| December 31, 2020 | 3.054M |
| September 30, 2020 | 1.709M |
| June 30, 2020 | 1.954M |
| March 31, 2020 | 2.126M |
| December 31, 2019 | 2.465M |
| September 30, 2019 | 3.616M |
| June 30, 2019 | 4.803M |
| Date | Value |
|---|---|
| March 31, 2019 | 8.531M |
| December 31, 2018 | 6.304M |
| September 30, 2018 | 13.33M |
| June 30, 2018 | 10.49M |
| March 31, 2018 | 11.64M |
| December 31, 2017 | 5.536M |
| September 30, 2017 | 6.293M |
| June 30, 2017 | 4.65M |
| March 31, 2017 | 4.114M |
| December 31, 2016 | 7.963M |
| September 30, 2016 | 4.287M |
| June 30, 2016 | 4.988M |
| March 31, 2016 | 3.234M |
| December 31, 2015 | 4.716M |
| September 30, 2015 | 4.328M |
| June 30, 2015 | 2.768M |
| March 31, 2015 | 2.119M |
| December 31, 2014 | 5.911M |
| September 30, 2014 | 3.253M |
| June 30, 2014 | 1.715M |
| March 31, 2014 | 1.038M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.709M
Minimum
Sep 2020
22.46M
Maximum
Jun 2022
6.387M
Average
3.082M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | 219.76M |
| Vanda Pharmaceuticals Inc | 16.66M |
| BioCardia Inc | 0.80M |
| Xeris Biopharma Holdings Inc | 5.759M |
| Instil Bio Inc | 2.921M |